Trials / Completed
CompletedNCT02750891
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with recurrent and relapsed diffuse intrinsic pontine glioma, glioblastoma, or grade III or IV glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSP-7888 | Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2016-04-26
- Last updated
- 2022-04-12
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02750891. Inclusion in this directory is not an endorsement.